Pay in 4 interest-free payments of $5.80 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
PMID 22856683
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b trial
The total radioactivity concentrations in the kidney, liver, stomach wall, thymus, spleen, intestine, lung, skin, and body fat were reduced by approximately 50% compared with the peak concentration in the same tissue (1 h after administration)
They act as incretin hormone mimetics
Sources Fay Nutrition has strict sourcing guidelines and relies on peer-reviewed studies, academic research institutions, and medical associations
US$ 26.66
US$ 29.55
US$ 24.84
US$ 22.20
US$ 26.47
US$ 21.40
